Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
BioAtla reports Q1 net loss $18.7M vs. $1.6M a year ago » 18:31
05/12/21
05/12
18:31
05/12/21
18:31
BCAB

BioAtla

$47.75 /

+0.79 (+1.68%)

Cash and cash equivalents…

Cash and cash equivalents as of March 31, 2021 were $221.2M. The company expects current cash and cash equivalents will be sufficient to fund planned operations into 2023. "BioAtla is rapidly advancing potentially registration-enabling Phase 2 clinical trials for our two lead CAB product candidates. With strong financial resources, we are also broadening our development pipeline to include several additional ADC and bispecific CAB candidates," stated CEO Jay Short. "Our clinical objectives in 2021 include providing Phase 2 interim data readouts by year-end for CAB-AXL-ADC and CAB-ROR2-ADC. Our Phase 1 trials for these product candidates demonstrated encouraging results in hard to treat cancer indications, particularly in patients with late-stage disease refractory to other lines of therapy," added Scott Smith, President.

ShowHide Related Items >><<
BCAB BioAtla
$47.75 /

+0.79 (+1.68%)

05/04/21 Credit Suisse
BioAtla assumed with an Outperform at Credit Suisse
05/04/21 JPMorgan
BioAtla price target raised to $64 from $45 at JPMorgan
04/26/21 Credit Suisse
BioAtla assumed with an Outperform at Credit Suisse
03/26/21 BTIG
BioAtla price target raised to $87 from $47 at BTIG
  • 16
    Dec
BCAB BioAtla
$47.75 /

+0.79 (+1.68%)

Over a week ago
Initiation
BioAtla assumed with an Outperform at Credit Suisse » 16:15
05/04/21
05/04
16:15
05/04/21
16:15
BCAB

BioAtla

$45.73 /

-1.67 (-3.52%)

Credit Suisse analyst…

Credit Suisse analyst Tiago Fauth assumed coverage of BioAtla with an Outperform rating and $68 price target. The analyst made no changes to the firm's rating, target price, or estimates.

ShowHide Related Items >><<
BCAB BioAtla
$45.73 /

-1.67 (-3.52%)

05/04/21 JPMorgan
BioAtla price target raised to $64 from $45 at JPMorgan
04/26/21 Credit Suisse
BioAtla assumed with an Outperform at Credit Suisse
03/26/21 BTIG
BioAtla price target raised to $87 from $47 at BTIG
01/11/21 JPMorgan
BioAtla initiated with an Overweight at JPMorgan
  • 16
    Dec
BCAB BioAtla
$45.73 /

-1.67 (-3.52%)

Recommendations
BioAtla price target raised to $64 from $45 at JPMorgan » 07:40
05/04/21
05/04
07:40
05/04/21
07:40
BCAB

BioAtla

/

+

JPMorgan analyst Anupam…

JPMorgan analyst Anupam Rama raised the firm's price target on BioAtla to $64 from $45 and keeps an Overweight rating on the shares after recently taking over coverage of the name. The analyst views the initial Phase 1 data for lead antibody drug conjugate conditionally active biologics BA3011 and BA3021 as "de-risking." Both programs have catalysts in the second half of 2021, which have the potential to increase both probability of success and peak sales estimates as well as add validation to the platform overall, Rama tells investors in a research note.

ShowHide Related Items >><<
BCAB BioAtla
/

+

04/26/21 Credit Suisse
BioAtla assumed with an Outperform at Credit Suisse
03/26/21 BTIG
BioAtla price target raised to $87 from $47 at BTIG
01/11/21 JPMorgan
BioAtla initiated with an Overweight at JPMorgan
01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
  • 16
    Dec
BCAB BioAtla
/

+

Initiation
BioAtla assumed with an Outperform at Credit Suisse » 06:48
04/26/21
04/26
06:48
04/26/21
06:48
BCAB

BioAtla

$50.33 /

+1.76 (+3.62%)

Credit Suisse analyst…

Credit Suisse analyst Brad Canino assumed coverage of BioAtla with an unchanged Outperform rating and $68 price target.

ShowHide Related Items >><<
BCAB BioAtla
$50.33 /

+1.76 (+3.62%)

03/26/21 BTIG
BioAtla price target raised to $87 from $47 at BTIG
01/11/21 JPMorgan
BioAtla initiated with an Overweight at JPMorgan
01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
01/11/21 Jefferies
BioAtla initiated with a Buy at Jefferies
  • 16
    Dec
BCAB BioAtla
$50.33 /

+1.76 (+3.62%)

Over a month ago
Recommendations
BioAtla price target raised to $87 from $47 at BTIG » 06:26
03/26/21
03/26
06:26
03/26/21
06:26
BCAB

BioAtla

$60.54 /

-4 (-6.20%)

BTIG analyst Thomas…

BTIG analyst Thomas Shrader raised the firm's price target on BioAtla to $87 from $47 and keeps a Buy rating on the shares. The company's Q4 results suggest that it has enough cash to last until 2024, the analyst tells investors in a research note, adding that he is modifying his model to include the BA3142 and BA3182 bispecifics programs to reflect the initial commercial opportunity in metastatic castrate-resistant prostate cancer.

ShowHide Related Items >><<
BCAB BioAtla
$60.54 /

-4 (-6.20%)

01/11/21 JPMorgan
BioAtla initiated with an Overweight at JPMorgan
01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
01/11/21 Jefferies
BioAtla initiated with a Buy at Jefferies
01/11/21 BTIG
BioAtla initiated with a Buy at BTIG
  • 16
    Dec
BCAB BioAtla
$60.54 /

-4 (-6.20%)

Over a quarter ago
Conference/Events
JPMorgan to hold a virtual conference » 04:55
01/14/21
01/14
04:55
01/14/21
04:55
ABMD

Abiomed

$323.77 /

-1.24 (-0.38%)

, AGIO

Agios Pharmaceuticals

$46.48 /

-0.06 (-0.13%)

, AHCO

AdaptHealth

$36.94 /

+0.165 (+0.45%)

, BCAB

BioAtla

$44.92 /

+3.54 (+8.55%)

, NXGN

NextGen Healthcare

$21.27 /

+0.79 (+3.86%)

, OLMA

Olema Oncology

$41.90 /

-0.07 (-0.17%)

, PCRX

Pacira

$73.50 /

+0.39 (+0.53%)

, BIIB

Biogen

$266.71 /

-0.81 (-0.30%)

, ESPR

Esperion

$26.94 /

-3.335 (-11.02%)

, EXEL

Exelixis

$24.38 /

-0.845 (-3.35%)

, HQY

HealthEquity

$75.73 /

-0.25 (-0.33%)

, MORF

Morphic

$30.30 /

+0.29 (+0.97%)

, NNOX

Nano-X Imaging

$54.30 /

+2.66 (+5.15%)

, SRPT

Sarepta

$87.22 /

+0.03 (+0.03%)

, SHC

Sotera Health

$25.01 /

-0.19 (-0.75%)

, RVNC

Revance

$29.02 /

-0.45 (-1.53%)

, RUBY

Rubius Therapeutics

$8.89 /

-0.28 (-3.05%)

, ZYME

Zymeworks

$52.97 /

-0.87 (-1.62%)

39th Annual Healthcare…

39th Annual Healthcare Virtual Conference will be held on January 11-14.

ShowHide Related Items >><<
ZYME Zymeworks
$52.97 /

-0.87 (-1.62%)

SRPT Sarepta
$87.22 /

+0.03 (+0.03%)

SHC Sotera Health
$25.01 /

-0.19 (-0.75%)

RVNC Revance
$29.02 /

-0.45 (-1.53%)

RUBY Rubius Therapeutics
$8.89 /

-0.28 (-3.05%)

PCRX Pacira
$73.50 /

+0.39 (+0.53%)

NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

MORF Morphic
$30.30 /

+0.29 (+0.97%)

HQY HealthEquity
$75.73 /

-0.25 (-0.33%)

EXEL Exelixis
$24.38 /

-0.845 (-3.35%)

ESPR Esperion
$26.94 /

-3.335 (-11.02%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

AHCO AdaptHealth
$36.94 /

+0.165 (+0.45%)

AGIO Agios Pharmaceuticals
$46.48 /

-0.06 (-0.13%)

ABMD Abiomed
$323.77 /

-1.24 (-0.38%)

ABMD Abiomed
$323.77 /

-1.24 (-0.38%)

12/21/20 SVB Leerink
Abiomed price target raised to $320 from $280 at SVB Leerink
12/14/20 Piper Sandler
Abiomed gets approval for XR sheath, says Piper Sandler
10/20/20 Piper Sandler
Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
AGIO Agios Pharmaceuticals
$46.48 /

-0.06 (-0.13%)

12/23/20 Citi
Agios shares 'significantly undervalued at this point,' says Citi
12/22/20 SVB Leerink
Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink
12/22/20 Cantor Fitzgerald
Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald
12/22/20 Barclays
Agios could enter 2022 with a third fewer shares, says Barclays
AHCO AdaptHealth
$36.94 /

+0.165 (+0.45%)

01/07/21 Canaccord
AdaptHealth price target raised to $50 from $39 at Canaccord
12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
BCAB BioAtla
$44.92 /

+3.54 (+8.55%)

01/11/21 JPMorgan
BioAtla initiated with an Overweight at JPMorgan
01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
01/11/21 Jefferies
BioAtla initiated with a Buy at Jefferies
01/11/21 BTIG
BioAtla initiated with a Buy at BTIG
NXGN NextGen Healthcare
$21.27 /

+0.79 (+3.86%)

10/23/20 SVB Leerink
NextGen Healthcare price target raised to $14 from $12 at SVB Leerink
10/23/20 Piper Sandler
NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler
07/31/20 Piper Sandler
NextGen Healthcare price target raised to $23 from $17 at Piper Sandler
06/02/20 Deutsche Bank
NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank
OLMA Olema Oncology
$41.90 /

-0.07 (-0.17%)

12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
12/14/20 Canaccord
Olema Pharmaceuticals initiated with a Buy at Canaccord
12/14/20 Cowen
Olema Pharmaceuticals initiated with an Outperform at Cowen
PCRX Pacira
$73.50 /

+0.39 (+0.53%)

01/06/21 RBC Capital
Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas
12/14/20 Barclays
Pacira price target raised to $79 from $73 at Barclays
09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
BIIB Biogen
$266.71 /

-0.81 (-0.30%)

01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
12/01/20 Raymond James
Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James
ESPR Esperion
$26.94 /

-3.335 (-11.02%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
EXEL Exelixis
$24.38 /

-0.845 (-3.35%)

12/14/20 William Blair
Calithera risk/reward attractive into CANTATA readout, says William Blair
10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
HQY HealthEquity
$75.73 /

-0.25 (-0.33%)

01/06/21 BTIG
HealthEquity initiated with a Neutral at BTIG
01/06/21 Deutsche Bank
HealthEquity price target raised to $77 from $60 at Deutsche Bank
12/08/20 Cantor Fitzgerald
HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald
12/08/20 JPMorgan
HealthEquity price target raised to $72 from $61 at JPMorgan
MORF Morphic
$30.30 /

+0.29 (+0.97%)

10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

09/15/20 Cantor Fitzgerald
Cantor reiterates $70 target on Nano-X after 'unfounded' short report
09/15/20 Cantor Fitzgerald
Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald
09/15/20 Oppenheimer
Nano-X Imaging initiated with a Perform at Oppenheimer
09/15/20 Berenberg
Nano-X Imaging initiated with a Buy at Berenberg
SRPT Sarepta
$87.22 /

+0.03 (+0.03%)

01/12/21 Citi
Sarepta downgraded to Neutral from Buy at Citi
01/11/21
Fly Intel: Top five analyst downgrades
01/11/21 UBS
Sarepta downgraded to Neutral on 'unexpected negative' results at UBS
01/11/21 UBS
Sarepta downgraded to Neutral from Buy at UBS
SHC Sotera Health
$25.01 /

-0.19 (-0.75%)

01/13/21 Baird
Sotera Health initiated with an Outperform at Baird
12/15/20 KeyBanc
Sotera Health initiated with an Overweight at KeyBanc
12/15/20 JPMorgan
Sotera Health initiated with an Overweight at JPMorgan
12/15/20 Jefferies
Sotera Health initiated with a Buy at Jefferies
RVNC Revance
$29.02 /

-0.45 (-1.53%)

12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
RUBY Rubius Therapeutics
$8.89 /

-0.28 (-3.05%)

10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
ZYME Zymeworks
$52.97 /

-0.87 (-1.62%)

01/12/21 SVB Leerink
Zymeworks price target raised to $66 from $45 at SVB Leerink
01/12/21 Wells Fargo
Zymeworks price target raised to $71 from $58 at Wells Fargo
09/29/20 JPMorgan
Zymeworks resumed with a Neutral at JPMorgan
08/06/20
Fly Intel: Top analyst initiations
ZYME Zymeworks
$52.97 /

-0.87 (-1.62%)

SRPT Sarepta
$87.22 /

+0.03 (+0.03%)

SHC Sotera Health
$25.01 /

-0.19 (-0.75%)

RVNC Revance
$29.02 /

-0.45 (-1.53%)

RUBY Rubius Therapeutics
$8.89 /

-0.28 (-3.05%)

PCRX Pacira
$73.50 /

+0.39 (+0.53%)

NXGN NextGen Healthcare
$21.27 /

+0.79 (+3.86%)

NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

MORF Morphic
$30.30 /

+0.29 (+0.97%)

HQY HealthEquity
$75.73 /

-0.25 (-0.33%)

EXEL Exelixis
$24.38 /

-0.845 (-3.35%)

ESPR Esperion
$26.94 /

-3.335 (-11.02%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

AHCO AdaptHealth
$36.94 /

+0.165 (+0.45%)

AGIO Agios Pharmaceuticals
$46.48 /

-0.06 (-0.13%)

ABMD Abiomed
$323.77 /

-1.24 (-0.38%)

  • 06
    Jan
  • 15
    Dec
  • 16
    Dec
  • 19
    Nov
  • 20
    Nov
  • 03
    Sep
  • 21
    Aug
  • 09
    Jul
  • 01
    Jul
  • 12
    Feb
  • 23
    Jan
NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

SRPT Sarepta
$87.22 /

+0.03 (+0.03%)

RVNC Revance
$29.02 /

-0.45 (-1.53%)

OLMA Olema Oncology
$41.90 /

-0.07 (-0.17%)

NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

HQY HealthEquity
$75.73 /

-0.25 (-0.33%)

ESPR Esperion
$26.94 /

-3.335 (-11.02%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

BCAB BioAtla
$44.92 /

+3.54 (+8.55%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

HQY HealthEquity
$75.73 /

-0.25 (-0.33%)

ESPR Esperion
$26.94 /

-3.335 (-11.02%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

AHCO AdaptHealth
$36.94 /

+0.165 (+0.45%)

Conference/Events
JPMorgan to hold a virtual conference » 04:55
01/13/21
01/13
04:55
01/13/21
04:55
ABMD

Abiomed

$324.65 /

+0.28 (+0.09%)

, AGIO

Agios Pharmaceuticals

$46.54 /

-0.19 (-0.41%)

, AHCO

AdaptHealth

$36.78 /

-0.405 (-1.09%)

, BCAB

BioAtla

$41.38 /

+1.38 (+3.45%)

, NXGN

NextGen Healthcare

$20.50 /

+0.89 (+4.54%)

, OLMA

Olema Oncology

$41.97 /

+0.84 (+2.04%)

, PCRX

Pacira

$73.11 /

+1.46 (+2.04%)

, BIIB

Biogen

$267.44 /

-0.13 (-0.05%)

, ESPR

Esperion

$30.28 /

-1.01 (-3.23%)

, EXEL

Exelixis

$25.23 /

+1.1 (+4.56%)

, HQY

HealthEquity

$75.95 /

+1.83 (+2.47%)

, MORF

Morphic

$30.12 /

+0.27 (+0.90%)

, NNOX

Nano-X Imaging

$51.61 /

+0.22 (+0.43%)

, SRPT

Sarepta

$87.32 /

-2.46 (-2.74%)

, SHC

Sotera Health

$25.20 /

-0.39 (-1.52%)

, RVNC

Revance

$29.47 /

+0.46 (+1.59%)

, RUBY

Rubius Therapeutics

$9.16 /

+0.12 (+1.33%)

, ZYME

Zymeworks

$53.99 /

-2.49 (-4.41%)

39th Annual Healthcare…

39th Annual Healthcare Virtual Conference will be held on January 11-14.

ShowHide Related Items >><<
ZYME Zymeworks
$53.99 /

-2.49 (-4.41%)

SRPT Sarepta
$87.32 /

-2.46 (-2.74%)

SHC Sotera Health
$25.20 /

-0.39 (-1.52%)

RVNC Revance
$29.47 /

+0.46 (+1.59%)

RUBY Rubius Therapeutics
$9.16 /

+0.12 (+1.33%)

PCRX Pacira
$73.11 /

+1.46 (+2.04%)

NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

MORF Morphic
$30.12 /

+0.27 (+0.90%)

HQY HealthEquity
$75.95 /

+1.83 (+2.47%)

EXEL Exelixis
$25.23 /

+1.1 (+4.56%)

ESPR Esperion
$30.28 /

-1.01 (-3.23%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

AHCO AdaptHealth
$36.78 /

-0.405 (-1.09%)

AGIO Agios Pharmaceuticals
$46.54 /

-0.19 (-0.41%)

ABMD Abiomed
$324.65 /

+0.28 (+0.09%)

ABMD Abiomed
$324.65 /

+0.28 (+0.09%)

12/21/20 SVB Leerink
Abiomed price target raised to $320 from $280 at SVB Leerink
12/14/20 Piper Sandler
Abiomed gets approval for XR sheath, says Piper Sandler
10/20/20 Piper Sandler
Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
AGIO Agios Pharmaceuticals
$46.54 /

-0.19 (-0.41%)

12/23/20 Citi
Agios shares 'significantly undervalued at this point,' says Citi
12/22/20 SVB Leerink
Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink
12/22/20 Cantor Fitzgerald
Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald
12/22/20 Barclays
Agios could enter 2022 with a third fewer shares, says Barclays
AHCO AdaptHealth
$36.78 /

-0.405 (-1.09%)

01/07/21 Canaccord
AdaptHealth price target raised to $50 from $39 at Canaccord
12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
BCAB BioAtla
$41.38 /

+1.38 (+3.45%)

01/11/21 JPMorgan
BioAtla initiated with an Overweight at JPMorgan
01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
01/11/21 Jefferies
BioAtla initiated with a Buy at Jefferies
01/11/21 BTIG
BioAtla initiated with a Buy at BTIG
NXGN NextGen Healthcare
$20.50 /

+0.89 (+4.54%)

10/23/20 SVB Leerink
NextGen Healthcare price target raised to $14 from $12 at SVB Leerink
10/23/20 Piper Sandler
NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler
07/31/20 Piper Sandler
NextGen Healthcare price target raised to $23 from $17 at Piper Sandler
06/02/20 Deutsche Bank
NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank
OLMA Olema Oncology
$41.97 /

+0.84 (+2.04%)

12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
12/14/20 Canaccord
Olema Pharmaceuticals initiated with a Buy at Canaccord
12/14/20 Cowen
Olema Pharmaceuticals initiated with an Outperform at Cowen
PCRX Pacira
$73.11 /

+1.46 (+2.04%)

01/06/21 RBC Capital
Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas
12/14/20 Barclays
Pacira price target raised to $79 from $73 at Barclays
09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
BIIB Biogen
$267.44 /

-0.13 (-0.05%)

01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
12/01/20 Raymond James
Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James
ESPR Esperion
$30.28 /

-1.01 (-3.23%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
EXEL Exelixis
$25.23 /

+1.1 (+4.56%)

12/14/20 William Blair
Calithera risk/reward attractive into CANTATA readout, says William Blair
10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
HQY HealthEquity
$75.95 /

+1.83 (+2.47%)

01/06/21 BTIG
HealthEquity initiated with a Neutral at BTIG
01/06/21 Deutsche Bank
HealthEquity price target raised to $77 from $60 at Deutsche Bank
12/08/20 Cantor Fitzgerald
HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald
12/08/20 JPMorgan
HealthEquity price target raised to $72 from $61 at JPMorgan
MORF Morphic
$30.12 /

+0.27 (+0.90%)

10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

09/15/20 Cantor Fitzgerald
Cantor reiterates $70 target on Nano-X after 'unfounded' short report
09/15/20 Cantor Fitzgerald
Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald
09/15/20 Oppenheimer
Nano-X Imaging initiated with a Perform at Oppenheimer
09/15/20 Berenberg
Nano-X Imaging initiated with a Buy at Berenberg
SRPT Sarepta
$87.32 /

-2.46 (-2.74%)

01/12/21 Citi
Sarepta downgraded to Neutral from Buy at Citi
01/11/21
Fly Intel: Top five analyst downgrades
01/11/21 UBS
Sarepta downgraded to Neutral on 'unexpected negative' results at UBS
01/11/21 UBS
Sarepta downgraded to Neutral from Buy at UBS
SHC Sotera Health
$25.20 /

-0.39 (-1.52%)

12/15/20 KeyBanc
Sotera Health initiated with an Overweight at KeyBanc
12/15/20 JPMorgan
Sotera Health initiated with an Overweight at JPMorgan
12/15/20 Jefferies
Sotera Health initiated with a Buy at Jefferies
12/15/20 Citi
Sotera Health initiated with a Buy at Citi
RVNC Revance
$29.47 /

+0.46 (+1.59%)

12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
RUBY Rubius Therapeutics
$9.16 /

+0.12 (+1.33%)

10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
ZYME Zymeworks
$53.99 /

-2.49 (-4.41%)

01/12/21 SVB Leerink
Zymeworks price target raised to $66 from $45 at SVB Leerink
01/12/21 Wells Fargo
Zymeworks price target raised to $71 from $58 at Wells Fargo
09/29/20 JPMorgan
Zymeworks resumed with a Neutral at JPMorgan
08/06/20
Fly Intel: Top analyst initiations
ZYME Zymeworks
$53.99 /

-2.49 (-4.41%)

SRPT Sarepta
$87.32 /

-2.46 (-2.74%)

SHC Sotera Health
$25.20 /

-0.39 (-1.52%)

RVNC Revance
$29.47 /

+0.46 (+1.59%)

RUBY Rubius Therapeutics
$9.16 /

+0.12 (+1.33%)

PCRX Pacira
$73.11 /

+1.46 (+2.04%)

NXGN NextGen Healthcare
$20.50 /

+0.89 (+4.54%)

NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

MORF Morphic
$30.12 /

+0.27 (+0.90%)

HQY HealthEquity
$75.95 /

+1.83 (+2.47%)

EXEL Exelixis
$25.23 /

+1.1 (+4.56%)

ESPR Esperion
$30.28 /

-1.01 (-3.23%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

AHCO AdaptHealth
$36.78 /

-0.405 (-1.09%)

AGIO Agios Pharmaceuticals
$46.54 /

-0.19 (-0.41%)

ABMD Abiomed
$324.65 /

+0.28 (+0.09%)

  • 06
    Jan
  • 15
    Dec
  • 16
    Dec
  • 19
    Nov
  • 20
    Nov
  • 03
    Sep
  • 21
    Aug
  • 09
    Jul
  • 01
    Jul
  • 12
    Feb
  • 23
    Jan
NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

SRPT Sarepta
$87.32 /

-2.46 (-2.74%)

RVNC Revance
$29.47 /

+0.46 (+1.59%)

OLMA Olema Oncology
$41.97 /

+0.84 (+2.04%)

NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

HQY HealthEquity
$75.95 /

+1.83 (+2.47%)

ESPR Esperion
$30.28 /

-1.01 (-3.23%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

BCAB BioAtla
$41.38 /

+1.38 (+3.45%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

HQY HealthEquity
$75.95 /

+1.83 (+2.47%)

ESPR Esperion
$30.28 /

-1.01 (-3.23%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

AHCO AdaptHealth
$36.78 /

-0.405 (-1.09%)

Conference/Events
JPMorgan to hold a virtual conference » 04:55
01/12/21
01/12
04:55
01/12/21
04:55
ABMD

Abiomed

$324.31 /

+0.31 (+0.10%)

, AGIO

Agios Pharmaceuticals

$46.71 /

+0.81 (+1.76%)

, AHCO

AdaptHealth

$37.18 /

-1.06 (-2.77%)

, BCAB

BioAtla

$40.00 /

+1.79 (+4.68%)

, NXGN

NextGen Healthcare

$19.60 /

-0.26 (-1.31%)

, OLMA

Olema Oncology

$41.65 /

-0.84 (-1.98%)

, PCRX

Pacira

$71.65 /

+1.58 (+2.25%)

, BIIB

Biogen

$267.53 /

+15.17 (+6.01%)

, ESPR

Esperion

$31.29 /

+0.25 (+0.81%)

, EXEL

Exelixis

$24.13 /

+1.3 (+5.69%)

, HQY

HealthEquity

$74.12 /

-1.03 (-1.37%)

, MORF

Morphic

$29.83 /

-0.64 (-2.10%)

, NNOX

Nano-X Imaging

$51.39 /

-1.625 (-3.07%)

, SRPT

Sarepta

$89.78 /

+7.48 (+9.09%)

, SHC

Sotera Health

$25.59 /

+0.59 (+2.36%)

, RVNC

Revance

$29.00 /

-0.41 (-1.39%)

, RUBY

Rubius Therapeutics

$9.03 /

-0.47 (-4.95%)

, ZYME

Zymeworks

$56.48 /

-0.45 (-0.79%)

39th Annual Healthcare…

39th Annual Healthcare Virtual Conference will be held on January 11-14.

ShowHide Related Items >><<
ZYME Zymeworks
$56.48 /

-0.45 (-0.79%)

SRPT Sarepta
$89.78 /

+7.48 (+9.09%)

SHC Sotera Health
$25.59 /

+0.59 (+2.36%)

RVNC Revance
$29.00 /

-0.41 (-1.39%)

RUBY Rubius Therapeutics
$9.03 /

-0.47 (-4.95%)

PCRX Pacira
$71.65 /

+1.58 (+2.25%)

NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

MORF Morphic
$29.83 /

-0.64 (-2.10%)

HQY HealthEquity
$74.12 /

-1.03 (-1.37%)

EXEL Exelixis
$24.13 /

+1.3 (+5.69%)

ESPR Esperion
$31.29 /

+0.25 (+0.81%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

AHCO AdaptHealth
$37.18 /

-1.06 (-2.77%)

AGIO Agios Pharmaceuticals
$46.71 /

+0.81 (+1.76%)

ABMD Abiomed
$324.31 /

+0.31 (+0.10%)

ABMD Abiomed
$324.31 /

+0.31 (+0.10%)

12/21/20 SVB Leerink
Abiomed price target raised to $320 from $280 at SVB Leerink
12/14/20 Piper Sandler
Abiomed gets approval for XR sheath, says Piper Sandler
10/20/20 Piper Sandler
Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
AGIO Agios Pharmaceuticals
$46.71 /

+0.81 (+1.76%)

12/23/20 Citi
Agios shares 'significantly undervalued at this point,' says Citi
12/22/20 SVB Leerink
Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink
12/22/20 Cantor Fitzgerald
Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald
12/22/20 Barclays
Agios could enter 2022 with a third fewer shares, says Barclays
AHCO AdaptHealth
$37.18 /

-1.06 (-2.77%)

01/07/21 Canaccord
AdaptHealth price target raised to $50 from $39 at Canaccord
12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
BCAB BioAtla
$40.00 /

+1.79 (+4.68%)

01/11/21 JPMorgan
BioAtla initiated with an Overweight at JPMorgan
01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
01/11/21 Jefferies
BioAtla initiated with a Buy at Jefferies
01/11/21 BTIG
BioAtla initiated with a Buy at BTIG
NXGN NextGen Healthcare
$19.60 /

-0.26 (-1.31%)

10/23/20 SVB Leerink
NextGen Healthcare price target raised to $14 from $12 at SVB Leerink
10/23/20 Piper Sandler
NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler
07/31/20 Piper Sandler
NextGen Healthcare price target raised to $23 from $17 at Piper Sandler
06/02/20 Deutsche Bank
NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank
OLMA Olema Oncology
$41.65 /

-0.84 (-1.98%)

12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
12/14/20 Canaccord
Olema Pharmaceuticals initiated with a Buy at Canaccord
12/14/20 Cowen
Olema Pharmaceuticals initiated with an Outperform at Cowen
PCRX Pacira
$71.65 /

+1.58 (+2.25%)

01/06/21 RBC Capital
Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas
12/14/20 Barclays
Pacira price target raised to $79 from $73 at Barclays
09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
BIIB Biogen
$267.53 /

+15.17 (+6.01%)

01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
12/01/20 Raymond James
Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James
ESPR Esperion
$31.29 /

+0.25 (+0.81%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
EXEL Exelixis
$24.13 /

+1.3 (+5.69%)

12/14/20 William Blair
Calithera risk/reward attractive into CANTATA readout, says William Blair
10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
HQY HealthEquity
$74.12 /

-1.03 (-1.37%)

01/06/21 BTIG
HealthEquity initiated with a Neutral at BTIG
01/06/21 Deutsche Bank
HealthEquity price target raised to $77 from $60 at Deutsche Bank
12/08/20 Cantor Fitzgerald
HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald
12/08/20 JPMorgan
HealthEquity price target raised to $72 from $61 at JPMorgan
MORF Morphic
$29.83 /

-0.64 (-2.10%)

10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

09/15/20 Cantor Fitzgerald
Cantor reiterates $70 target on Nano-X after 'unfounded' short report
09/15/20 Cantor Fitzgerald
Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald
09/15/20 Oppenheimer
Nano-X Imaging initiated with a Perform at Oppenheimer
09/15/20 Berenberg
Nano-X Imaging initiated with a Buy at Berenberg
SRPT Sarepta
$89.78 /

+7.48 (+9.09%)

01/11/21
Fly Intel: Top five analyst downgrades
01/11/21 UBS
Sarepta downgraded to Neutral on 'unexpected negative' results at UBS
01/11/21 UBS
Sarepta downgraded to Neutral from Buy at UBS
01/08/21 Chardan
Solid Biosciences selloff on Sarepta news a buying opportunity, says Chardan
SHC Sotera Health
$25.59 /

+0.59 (+2.36%)

12/15/20 KeyBanc
Sotera Health initiated with an Overweight at KeyBanc
12/15/20 JPMorgan
Sotera Health initiated with an Overweight at JPMorgan
12/15/20 Jefferies
Sotera Health initiated with a Buy at Jefferies
12/15/20 Citi
Sotera Health initiated with a Buy at Citi
RVNC Revance
$29.00 /

-0.41 (-1.39%)

12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
RUBY Rubius Therapeutics
$9.03 /

-0.47 (-4.95%)

10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
ZYME Zymeworks
$56.48 /

-0.45 (-0.79%)

09/29/20 JPMorgan
Zymeworks resumed with a Neutral at JPMorgan
08/06/20
Fly Intel: Top analyst initiations
08/06/20 SVB Leerink
SVB Leerink bullish on Zymeworks, initiates with an Outperform
08/06/20 SVB Leerink
Zymeworks initiated with an Outperform at SVB Leerink
ZYME Zymeworks
$56.48 /

-0.45 (-0.79%)

SRPT Sarepta
$89.78 /

+7.48 (+9.09%)

SHC Sotera Health
$25.59 /

+0.59 (+2.36%)

RVNC Revance
$29.00 /

-0.41 (-1.39%)

RUBY Rubius Therapeutics
$9.03 /

-0.47 (-4.95%)

PCRX Pacira
$71.65 /

+1.58 (+2.25%)

NXGN NextGen Healthcare
$19.60 /

-0.26 (-1.31%)

NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

MORF Morphic
$29.83 /

-0.64 (-2.10%)

HQY HealthEquity
$74.12 /

-1.03 (-1.37%)

EXEL Exelixis
$24.13 /

+1.3 (+5.69%)

ESPR Esperion
$31.29 /

+0.25 (+0.81%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

AHCO AdaptHealth
$37.18 /

-1.06 (-2.77%)

AGIO Agios Pharmaceuticals
$46.71 /

+0.81 (+1.76%)

ABMD Abiomed
$324.31 /

+0.31 (+0.10%)

  • 06
    Jan
  • 15
    Dec
  • 16
    Dec
  • 19
    Nov
  • 20
    Nov
  • 03
    Sep
  • 21
    Aug
  • 09
    Jul
  • 01
    Jul
  • 12
    Feb
  • 23
    Jan
NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

SRPT Sarepta
$89.78 /

+7.48 (+9.09%)

RVNC Revance
$29.00 /

-0.41 (-1.39%)

OLMA Olema Oncology
$41.65 /

-0.84 (-1.98%)

NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

HQY HealthEquity
$74.12 /

-1.03 (-1.37%)

ESPR Esperion
$31.29 /

+0.25 (+0.81%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

BCAB BioAtla
$40.00 /

+1.79 (+4.68%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

HQY HealthEquity
$74.12 /

-1.03 (-1.37%)

ESPR Esperion
$31.29 /

+0.25 (+0.81%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

AHCO AdaptHealth
$37.18 /

-1.06 (-2.77%)

Initiation
BioAtla initiated with an Overweight at JPMorgan » 09:50
01/11/21
01/11
09:50
01/11/21
09:50
BCAB

BioAtla

$38.65 /

+0.44 (+1.15%)

JPMorgan analyst Matthew…

JPMorgan analyst Matthew Holt initiated coverage of BioAtla with an Overweight rating and $45 price target. The company's conditionally active biologics platform has "broad potential" across many different solid tumors with meaningful advantages when compared with other approaches, Holt tells investors in a research note. He sees upside to the current valuation ahead of a string of clinical catalysts expected in 2021.

ShowHide Related Items >><<
BCAB BioAtla
$38.65 /

+0.44 (+1.15%)

01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
01/11/21 Jefferies
BioAtla initiated with a Buy at Jefferies
01/11/21 BTIG
BioAtla initiated with a Buy at BTIG
  • 16
    Dec
BCAB BioAtla
$38.65 /

+0.44 (+1.15%)

Conference/Events
JPMorgan to hold a virtual conference » 09:44
01/11/21
01/11
09:44
01/11/21
09:44
ABMD

Abiomed

$324.00 /

+ (+0.00%)

, AGIO

Agios Pharmaceuticals

$45.85 /

-0.05 (-0.11%)

, AHCO

AdaptHealth

$38.24 /

+ (+0.00%)

, BCAB

BioAtla

$38.22 /

+0.01 (+0.03%)

, NXGN

NextGen Healthcare

$19.92 /

+0.06 (+0.30%)

, OLMA

Olema Oncology

$42.48 /

-0.01 (-0.02%)

, PCRX

Pacira

$70.03 /

-0.04 (-0.06%)

, BIIB

Biogen

$252.57 /

+0.21 (+0.08%)

, ESPR

Esperion

$31.04 /

+ (+0.00%)

, EXEL

Exelixis

$22.84 /

+0.01 (+0.04%)

, HQY

HealthEquity

$75.22 /

+0.07 (+0.09%)

, MORF

Morphic

$30.47 /

+ (+0.00%)

, NNOX

Nano-X Imaging

$53.02 /

+ (+0.00%)

, SRPT

Sarepta

$82.30 /

+ (+0.00%)

, SHC

Sotera Health

$25.00 /

+ (+0.00%)

, RVNC

Revance

$29.41 /

+ (+0.00%)

, RUBY

Rubius Therapeutics

$9.50 /

+ (+0.00%)

, ZYME

Zymeworks

$56.95 /

+0.02 (+0.04%)

39th Annual Healthcare…

39th Annual Healthcare Virtual Conference will be held on January 11-14.

ShowHide Related Items >><<
ZYME Zymeworks
$56.95 /

+0.02 (+0.04%)

SRPT Sarepta
$82.30 /

+ (+0.00%)

SHC Sotera Health
$25.00 /

+ (+0.00%)

RVNC Revance
$29.41 /

+ (+0.00%)

RUBY Rubius Therapeutics
$9.50 /

+ (+0.00%)

PCRX Pacira
$70.03 /

-0.04 (-0.06%)

NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

MORF Morphic
$30.47 /

+ (+0.00%)

HQY HealthEquity
$75.22 /

+0.07 (+0.09%)

EXEL Exelixis
$22.84 /

+0.01 (+0.04%)

ESPR Esperion
$31.04 /

+ (+0.00%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

AHCO AdaptHealth
$38.24 /

+ (+0.00%)

AGIO Agios Pharmaceuticals
$45.85 /

-0.05 (-0.11%)

ABMD Abiomed
$324.00 /

+ (+0.00%)

ABMD Abiomed
$324.00 /

+ (+0.00%)

12/21/20 SVB Leerink
Abiomed price target raised to $320 from $280 at SVB Leerink
12/14/20 Piper Sandler
Abiomed gets approval for XR sheath, says Piper Sandler
10/20/20 Piper Sandler
Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
AGIO Agios Pharmaceuticals
$45.85 /

-0.05 (-0.11%)

12/23/20 Citi
Agios shares 'significantly undervalued at this point,' says Citi
12/22/20 SVB Leerink
Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink
12/22/20 Cantor Fitzgerald
Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald
12/22/20 Barclays
Agios could enter 2022 with a third fewer shares, says Barclays
AHCO AdaptHealth
$38.24 /

+ (+0.00%)

01/07/21 Canaccord
AdaptHealth price target raised to $50 from $39 at Canaccord
12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
BCAB BioAtla
$38.22 /

+0.01 (+0.03%)

01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
01/11/21 Jefferies
BioAtla initiated with a Buy at Jefferies
01/11/21 BTIG
BioAtla initiated with a Buy at BTIG
NXGN NextGen Healthcare
$19.92 /

+0.06 (+0.30%)

10/23/20 SVB Leerink
NextGen Healthcare price target raised to $14 from $12 at SVB Leerink
10/23/20 Piper Sandler
NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler
07/31/20 Piper Sandler
NextGen Healthcare price target raised to $23 from $17 at Piper Sandler
06/02/20 Deutsche Bank
NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank
OLMA Olema Oncology
$42.48 /

-0.01 (-0.02%)

12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
12/14/20 Canaccord
Olema Pharmaceuticals initiated with a Buy at Canaccord
12/14/20 Cowen
Olema Pharmaceuticals initiated with an Outperform at Cowen
PCRX Pacira
$70.03 /

-0.04 (-0.06%)

01/06/21 RBC Capital
Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas
12/14/20 Barclays
Pacira price target raised to $79 from $73 at Barclays
09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
BIIB Biogen
$252.57 /

+0.21 (+0.08%)

12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
12/01/20 Raymond James
Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James
12/01/20 Citi
Sage Therapeutics price target lowered to $93 from $100 at Citi
ESPR Esperion
$31.04 /

+ (+0.00%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
EXEL Exelixis
$22.84 /

+0.01 (+0.04%)

12/14/20 William Blair
Calithera risk/reward attractive into CANTATA readout, says William Blair
10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
HQY HealthEquity
$75.22 /

+0.07 (+0.09%)

01/06/21 BTIG
HealthEquity initiated with a Neutral at BTIG
01/06/21 Deutsche Bank
HealthEquity price target raised to $77 from $60 at Deutsche Bank
12/08/20 Cantor Fitzgerald
HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald
12/08/20 JPMorgan
HealthEquity price target raised to $72 from $61 at JPMorgan
MORF Morphic
$30.47 /

+ (+0.00%)

10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

09/15/20 Cantor Fitzgerald
Cantor reiterates $70 target on Nano-X after 'unfounded' short report
09/15/20 Cantor Fitzgerald
Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald
09/15/20 Oppenheimer
Nano-X Imaging initiated with a Perform at Oppenheimer
09/15/20 Berenberg
Nano-X Imaging initiated with a Buy at Berenberg
SRPT Sarepta
$82.30 /

+ (+0.00%)

01/11/21 UBS
Sarepta downgraded to Neutral on 'unexpected negative' results at UBS
01/11/21 UBS
Sarepta downgraded to Neutral from Buy at UBS
01/08/21 Chardan
Solid Biosciences selloff on Sarepta news a buying opportunity, says Chardan
01/08/21 JPMorgan
Sarepta downgraded to Underweight from Overweight at JPMorgan
SHC Sotera Health
$25.00 /

+ (+0.00%)

12/15/20 KeyBanc
Sotera Health initiated with an Overweight at KeyBanc
12/15/20 JPMorgan
Sotera Health initiated with an Overweight at JPMorgan
12/15/20 Jefferies
Sotera Health initiated with a Buy at Jefferies
12/15/20 Citi
Sotera Health initiated with a Buy at Citi
RVNC Revance
$29.41 /

+ (+0.00%)

12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
RUBY Rubius Therapeutics
$9.50 /

+ (+0.00%)

10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
ZYME Zymeworks
$56.95 /

+0.02 (+0.04%)

09/29/20 JPMorgan
Zymeworks resumed with a Neutral at JPMorgan
08/06/20
Fly Intel: Top analyst initiations
08/06/20 SVB Leerink
SVB Leerink bullish on Zymeworks, initiates with an Outperform
08/06/20 SVB Leerink
Zymeworks initiated with an Outperform at SVB Leerink
ZYME Zymeworks
$56.95 /

+0.02 (+0.04%)

SRPT Sarepta
$82.30 /

+ (+0.00%)

SHC Sotera Health
$25.00 /

+ (+0.00%)

RVNC Revance
$29.41 /

+ (+0.00%)

RUBY Rubius Therapeutics
$9.50 /

+ (+0.00%)

PCRX Pacira
$70.03 /

-0.04 (-0.06%)

NXGN NextGen Healthcare
$19.92 /

+0.06 (+0.30%)

NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

MORF Morphic
$30.47 /

+ (+0.00%)

HQY HealthEquity
$75.22 /

+0.07 (+0.09%)

EXEL Exelixis
$22.84 /

+0.01 (+0.04%)

ESPR Esperion
$31.04 /

+ (+0.00%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

AHCO AdaptHealth
$38.24 /

+ (+0.00%)

AGIO Agios Pharmaceuticals
$45.85 /

-0.05 (-0.11%)

ABMD Abiomed
$324.00 /

+ (+0.00%)

  • 06
    Jan
  • 15
    Dec
  • 16
    Dec
  • 19
    Nov
  • 20
    Nov
  • 03
    Sep
  • 21
    Aug
  • 09
    Jul
  • 01
    Jul
  • 12
    Feb
  • 23
    Jan
NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

SRPT Sarepta
$82.30 /

+ (+0.00%)

RVNC Revance
$29.41 /

+ (+0.00%)

OLMA Olema Oncology
$42.48 /

-0.01 (-0.02%)

NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

HQY HealthEquity
$75.22 /

+0.07 (+0.09%)

ESPR Esperion
$31.04 /

+ (+0.00%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

BCAB BioAtla
$38.22 /

+0.01 (+0.03%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

HQY HealthEquity
$75.22 /

+0.07 (+0.09%)

ESPR Esperion
$31.04 /

+ (+0.00%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

AHCO AdaptHealth
$38.24 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.